Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Banking heavily on APACHE III

Banking heavily on APACHE III

By Karen Bernstein Editor-in-ChiefThe physician who devised the modified APACHE III method of prospectively defining patients who will benefit from sepsis drugs hopes that the system will become the "common language" of sepsis trials, permitting comparison of future trials and allowing clinicians to consider the efficacy of cocktails of drugs.

William Knaus, director of the ICU research unit at the George Washington Medical Center in Washington, D.C., led a team of researchers that devised an APACHE III prognostic system specific to sepsis patients. The team applied the entry criteria for Synergen Inc.'s Phase III Antril IL-1ra trial to a database of 60,000 critically

Read the full 1079 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers